Fig. 2.

Subgroup analyses for OS in the NICT and PCT groups after a propensity score matching method according to age (A1: <65 years, A2: ≥65 years), ECOG-PS (B1: PS 0–1, B2: PS 2–4), histology (C1: adenocarcinoma, C2: squamous cell carcinoma), and PD-L1 TPS (D1: TPS ≥ 50%, D2: TPS 1–49%, D3: TPS < 1%). Abbreviations: NICT, nivolumab plus ipilimumab with chemotherapy; PCT, pembrolizumab with chemotherapy; mOS, median overall survival; HR, hazard ratio; NR, not reached; ECOG-PS, Eastern Cooperative Oncology Group Performance Status; PD-L1 TPS, programmed cell death ligand-1 tumor proportion score